Transaction #29379 · Form 4 · 0001193125-26-412466
Xilio Therapeutics, Inc. · Stock award · Stock Option (right to buy)
Xilio Therapeutics, Inc. · Transacted October 1, 2026 · Filed October 2, 2026
What does this filing report?
An SEC Form 4 filing for Xilio Therapeutics, Inc. records a stock award involving Stock Option (right to buy) on October 1, 2026. The reported quantity was 105,000. The filing date is October 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Xilio Therapeutics, Inc.
- Company CIK
- 0001840233
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 105,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 105,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 2, 2026, 4:33 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Houvras Yariv ↗
CHIEF MEDICAL OFFICER
CIK 0002154870
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 105,000
- Conversion / exercise price
- 8.91
- Exercise date
- Not reported
- Expiration date
- September 30, 2036
Filing footnotes & remarks
- F1
- The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.